[Latest] Global Serological Testing Market Size/Share Worth USD 8,100 Million by 2033 at a 6.70% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
19 nov. 2024 01h30 HE
|
Custom Market Insights
Austin, TX, USA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Serological Testing Market Size, Trends and Insights By Technology (ELISA, NAT,...
Theratechnologies dévoile le plan et les caractéristiques initiales de l'essai PROMISE-US sur l'ibalizumab chez les personnes vivant avec le VIH ayant reçu de nombreux traitements et présentant une multirésistance aux médicaments
17 oct. 2024 07h30 HE
|
Theratechnologies
MONTRÉAL, 17 oct. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au...
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
17 oct. 2024 07h30 HE
|
Theratechnologies
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
Theratechnologies présentera des données à l’IDWeek 2024 soulignant les progrès réalisés dans le traitement et la prise en charge des complications chez les personnes vivant avec le VIH
09 oct. 2024 07h30 HE
|
Theratechnologies
MONTRÉAL, 09 oct. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au...
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
09 oct. 2024 07h30 HE
|
Theratechnologies
MONTREAL, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
The Wistar Institute and University of Pennsylvania Scientists Identify Potential Target Gene within Certain HIV Reservoir Cells
03 oct. 2024 15h08 HE
|
The Wistar Institute
Philadelphia, PA, Oct. 03, 2024 (GLOBE NEWSWIRE) -- New findings could lead to different research tactics for scientists investigating a cure for HIV. Results from The Wistar Institute’s Lieberman...
Rita & Alex Hillman Foundation Awards $250,000 in Funding to Advance Early-Stage, Equity-Focused Health Innovations
24 sept. 2024 11h00 HE
|
Rita & Alex Hillman Foundation
RITA & ALEX HILLMAN FOUNDATION AWARDS $250,000 IN FUNDING FOR EARLY-STAGE, EQUITY-FOCUSED INNOVATIONS FOR VIOLENCE PREVENTION, BIRTH JUSTICE, HIV TESTING
Nika Pharmaceuticals, Inc. (NIKA) Signed a Distribution Agreement for Nigeria
18 juil. 2024 11h35 HE
|
Nika Pharmaceuticals, Inc.
Nika Pharmaceuticals, Inc. (OTCMKTS: NIKA) signed a distribution agreement for the Republic of Nigeria that can generate the company €7.9 billion revenue.
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
01 juil. 2024 16h31 HE
|
HOOKIPA Pharma Inc.
Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (Gilead), to be evaluated as a potential component of a curative regimen for human immunodeficiency...
bioLytical Donates 1200 HIV Testing Kits Across the United States to Support National HIV Testing Day
27 juin 2024 09h00 HE
|
bioLytical Laboratories Inc.
bioLytical helps boost testing with free HIV rapid test donations to KFF and the Greater Than HIV campaign to support national testing efforts